Skip to main content

100% Bacteria free eggs for use in production of human and animal vaccines

Project description

Eliminating bacterial contamination through eggs for vaccine development and production

In times when immunisation has become a universal demand, any practice that transforms vaccine production, facilitates the work of health service providers and enables a rapid response to global pandemics is extremely valuable. The EU-funded OvaVax project aims to become the go-to supplier of the world's first superior-quality germ-free eggs to the vaccine industry globally by 2021. The project is led by an innovation-based biotechnology company that utilises disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. The new process they are proposing will address the increasing demand for safe, fast and cost-effective solutions in vaccine manufacturing.

Call for proposal

H2020-SMEInst-2018-2020-2
See other projects for this call

Coordinator

OVAGEN GROUP LIMITED
Address
Carrentrila
F26PC79 Ballina
Ireland

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 356 812,50